Leading NR Company Faces Whistleblower Complaints, Core Selling Points Alleged to Lack Sufficient Evidence.
In the NAD+ precursor space, while numerous NMN brands remain locked in fierce competition, their long-standing rival NR has already achieved market dominance.
Whether you take Tru Niagen—endorsed by Li Ka-shing and sold at Watsons—Life Extension’s NAD+ cell regenerator, or Nestlé’s NR Longevity, the core raw material comes from the same company: Niagen Bioscience, formerly known as ChromaDex.
But this dominant position is now under threat. Recently, the National Advertising Division (NAD) of the Better Business Bureau ruled that many marketing claims for Niagen’s flagship NR supplement, Tru Niagen, lack sufficient evidence. For example, changes in physiological markers from increased NAD+ levels do not prove health benefits for the heart, brain, or anti-aging. All such claims must be revised or removed.[1]
Although the NAD is not a government regulator, but a self-regulatory body for the U.S. advertising industry, its rulings carry substantial industry influence. Failure to comply could result in the case being referred to official agencies such as the Federal Trade Commission (FTC) for further action.
This ruling is not just about Niagen or NR supplements—it strikes at the core logic of the entire NAD+ precursor industry: does raising NAD+ equal health and anti-aging benefits?
After rounds of regulatory uncertainty for NMN supplements, leading NR companies are now also facing scrutiny, and the entire sector appears to be under renewed review.
Niagen Faces Full-Scale Challenges: Clinical, Anti-Aging Claims, and Marketing
Niagen’s review was triggered by a whistleblower complaint from a competitor, Reus Research, which also operates in the NAD+ supplement space.
In 2025, Niagen was the first to file a complaint against Reus with the NAD over its advertising, forcing Reus to revise or remove multiple claims. Now Reus has struck back with a damaging counterattack.
The complaint covered numerous claims on Niagen’s website, e-commerce pages, and social media. After a full review, the NAD issued the following rulings:
1) Core Selling Points Ruled Unsubstantiated
As the leader in the NR industry, Niagen boasts a strong research advantage over competitors, having funded more than 40 clinical studies.[2] Its marketing has heavily emphasized claims such as “clinically proven to significantly boost NAD+ levels” as a core selling point.
However, the NAD ruled that while studies show its NR supplement may increase NAD+ under certain conditions, the research varies widely in design, study populations, duration, and endpoints. Using a broad, generalized “clinically proven” statement omits these limitations and risks misleading consumers.
The NAD recommended that if Niagen retains such language, it must clearly disclose sources and specific study conditions, rather than making absolute claims.
2) No Evidence for Health & Anti-Aging Benefits
Niagen has linked increased NAD+ levels from its supplements to benefits including heart health, brain function, immune support, metabolic performance, and even anti-aging.
The NAD ruled these connections lack direct evidence.
Existing research focuses largely on biomarkers and mechanistic changes, such as NAD+ levels, but does not prove these translate to meaningful, perceptible health improvements for consumers. In short, no evidence shows actual benefits for the heart, brain, or anti-aging.
Caption: From cells to the brain, Niagen claims boosting NAD+ delivers wide-ranging health benefits
3) Marketing Compliance Violations Highlighted
Beyond core claims, Niagen’s marketing practices were also criticized.
Some user testimonials and case studies were found to convey unsubstantiated health improvements, such as increased energy or enhanced physical function.
Additionally, many influencer promotions failed to clearly disclose commercial partnerships. The NAD ruled that clear disclosures must appear visually or verbally in such marketing videos.
To be fair, undisclosed paid partnerships are a clear violation on Niagen’s part. However, the issue of “biomarker changes ≠ actual health benefits” is widespread in the dietary supplement industry. Few products can provide conclusive functional evidence, yet many strongly imply such benefits in marketing.
As of press time, Niagen has responded and agreed to discontinue several high-profile disputed claims, including those related to reproductive health, sleep improvement, and “Made in the USA” messaging. However, the company plans to appeal the remaining core rulings.
This controversy stems from Niagen’s earlier attempts to suppress competitors. Given its current stage, this conflict feels almost inevitable: the NR leader is at its most successful—and most anxious.
In its 2025 financial results released this March,[3] Niagen delivered its strongest performance since founding:
Net sales: $129.4 million, up 30% year-over-year
Net profit: $17.4 million, more than double the previous year
These figures may seem modest compared to peers. For instance, IM8, David Beckham’s anti-aging supplement brand launched in November 2024, generated $60.1 million in its first 12 months, with projected 2026 revenue of $180–200 million.[4]
But for Niagen, this marks a milestone.
After over 20 years in the industry and near-monopoly over NR ingredients and supplements, the company had long operated at a loss, with cumulative deficits reaching hundreds of millions of dollars. It relied on repeated stock offerings to stay afloat, diluting equity and eroding investor confidence.
Niagen did not achieve full-year profitability until 2024, with a net profit of **$8.6 million**.[3] The 2025 net profit of $17.4 million signals a shift from turnaround to sustainable cash generation.
Despite strong momentum, the company remains highly dependent on NR supplements as its sole revenue driver, while competition in the NAD+ sector intensifies.
Late last year, NMN supplements returned to the market following a policy relaxation after a ban. Niagen publicly opposed the move and hinted at potential legal or industry actions. Meanwhile, new players like Reus have entered the NAD+ space, rapidly gaining share through platforms like TikTok.
Against this backdrop, Niagen is aggressively seeking new growth engines.
In recent years, the company has heavily promoted NAD+ intravenous therapy. Its pharmaceutical-grade Niagen IV is now used in nearly 1,200 medical clinics,[5] with price points often exceeding $100 per session, offering higher margins and partially bypassing supplement marketing restrictions.
However, medical injections carry regulatory risks, and their potential as a new cash cow remains uncertain.
Niagen is also expanding into beauty and topical products.
After launching Tru Niagen Beauty in late 2025, marketed to provide cellular support for skin, hair, and nails, the company plans to expand NR into more topical categories.
Yet against established beauty and skincare brands, the sustainability of this path remains unclear.
On the surface, Niagen has exited losses, achieved profitability, and is exploring new business lines. But beneath this success, heavy reliance on a single product and intense external competition persist. To some extent, its aggressive expansion feels like a proactive response to external pressure.
This caution is reflected in Niagen’s 2025 10-K filing.
While management expressed optimism during investor calls, projecting 10–15% revenue growth in 2026,[5] the formal annual report clearly outlines risks:[6]
Even with two consecutive profitable years, the company cannot guarantee sustained profitability. If earnings come under pressure, its stock price may suffer. Rising spending on sales, distribution, and commercialization is also expected to increase costs and compress margins.
In short, although Niagen has escaped its long period of losses, it is far from entering a safe zone.
Conclusion
For Niagen, the impact of this ruling extends far beyond revising advertising slogans.
For years, the company survived prolonged losses by relying on a widely accepted narrative: backed by extensive clinical research, it linked NR-driven NAD+ elevation to tangible health benefits, justifying premium pricing and brand trust.
Focus brought leadership, but also amplified risk. If its core NAD+ story unravels, Niagen will have few remaining cards to play.